Fundamental Research Division
The DRF at the CEA assemble approximately 6,000 scientists since January 2016.
Scientific result | Cancer | Gene and cell therapy
In a phase 2 clinical trial, scientists showed the efficiency of targeting cancer stem cells—an approach imagined and developed at the CEA François-Jacob Institute for the treatment of leukemia, chronic myeloid leukemia in particular.
Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept | Cancer
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.